Form 4: Arrowhead Pharmaceuticals Director Acquires Shares Through Restricted Stock Units

Mauro Ferrari, a director at Arrowhead Pharmaceuticals, acquired 16,733 shares of common stock through restricted stock units on December 18, 2024.

Summary

• Mauro Ferrari, a director of Arrowhead Pharmaceuticals, acquired 16,733 shares of common stock.
• The acquisition was made through restricted stock units at a price of $22.99 per share.
• These restricted stock units will vest in one installment on the first anniversary date.
• Following the transaction, Mr. Ferrari beneficially owns 77,514 shares of Arrowhead Pharmaceuticals stock.

Sentiment

Score: 6

Explanation: The document is a routine filing of a director acquiring shares, which is generally neutral to slightly positive as it indicates confidence. There is no negative information.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders when they make transactions in their company's stock. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the United States, ensuring transparency of insider transactions.
• The acquisition of shares through restricted stock units is a common form of compensation for directors and executives in the biotechnology industry.
• The vesting schedule of one year is also a typical practice for such grants.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment as it indicates a director's confidence in the company.

Key Dates

Keywords

Arrowhead Pharmaceuticals, ARWR, insider trading, Form 4, restricted stock units, share acquisition, Mauro Ferrari, director